

Serial No. 09/926,712


Response to Office Action of January 14, 2004

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1 (currently amended): A ~~serine protease inhibitor compound~~ of formula (I)



where R<sub>2</sub> represents

(i) phenyl optionally being substituted in the 3 and/or 4 position by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO<sub>2</sub>- or R<sub>1j</sub>, and optionally substituted at the 6 position by amino, hydroxy, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio; or

(ii) naphth-2-yl optionally substituted at the 6 or 7 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R<sub>1j</sub> and optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminoalkyl, alkoxy or alkylthio;

-X-X- is CONH;

~~R<sub>1j</sub>-R<sub>1a</sub>~~ represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxylalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

Serial No. 09/926,712

Response to Office Action of January 14, 2004

$R_1$  is as defined for  $R_{1j}$ - $R_{1a}$ , provided that  $R_1$  is not unsubstituted aminoalkyl;


$L$  is  ~~$CO$ ,  $CH_2NH$ ,  $CONR_{1d}(CH_2)_m$ ,  $(CH_2)_mN(R_{1d})CO(CH_2)_m$ ,  $(CH_2)_{m+2}$ ,  $CO(CH_2)_m$ ,  $(CH_2)_mCO$ ,  $(CH_2)_mOC-O$ ,  $(CH_2)_mO$ ,  $CH=CH(CH_2)_m$ ,  $SO_2$ ,  $SO_2NR_{1d}$ ,  $SO_2(CH_2)_m$ ,  $(CH_2)_mSO_2$  or  $(CH_2)_mSO_2NR_{1d}$  (where each  $m$  is independently 0 or 1 and  $R_{1d}$  is hydrogen);~~

$Y$  is a CH group;

$Cy$  is a saturated or unsaturated, mono or poly cyclic, homocyclic group optionally substituted by groups  $R_{3a}$  or phenyl optionally substituted by  $R_{3a}$ ;


each  $R_{3a}$  independently is  $R_{1c}$ , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl;

$Lp(D)_n$ - ~~$Lp$~~  is a lipophilic organic group selected from




Serial No. 09/926,712

Response to Office Action of January 14, 2004








Serial No. 09/926,712

Response to Office Action of January 14, 2004




Serial No. 09/926,712

Response to Office Action of January 14, 2004




Serial No. 09/926,712

Response to Office Action of January 14, 2004



Serial No. 09/926,712

Response to Office Action of January 14, 2004




Serial No. 09/926,712

Response to Office Action of January 14, 2004

wherein  $R_3$  is as defined for  $R_{3a}$ ; ~~$m$  represents 0 or 1;~~ $R_4$  represents hydrogen,  $(CH_2)_wCOOH$  or  $(CH_2)_wCONH_2$ ; $w$  represents an integer from 0 to 4; andwhen  $X$  is in the ring bonded to  $L$ ,  $X$  is N and, otherwise $X$  represents CH or N; ~~$D$  is a hydrogen bond donor group; and  $n$  is 0;~~~~or  $L-Lp(D)_n$  is:~~

(i)

~~in which  $q$  is 1 or 2;~~


~~$Q$  is a direct bond; and  $R_q$  is piperidin-4-yl which may bear a  $C_{1-3}$ alkyl substituent at the 1 position; or  $R_q$  is  $NR_aR_b$  in which each of  $R_a$  and  $R_b$  independently is hydrogen or  $C_{1-3}$ alkyl; or one of  $R_a$  and  $R_b$  is hydrogen or methyl and the other of  $R_a$  and  $R_b$  is  $-CH_2-R_c$  or  $-CH_2-R_d$  in which  $R_c$  is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl,  $CONH_2$ ,  $SO_2NH_2$ , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which  $R_d$  is isopropyl or cyclopentyl, or  $NR_aR_b$  is pyrrolidino, piperidino, morpholine, piperazino, or tetrahydro-1,4-diazepino in which a pyrrolidino or piperidino may be a 3,4-dihydro derivative and in which a pyrrolidino, piperidino, piperazino, or tetrahydro-1,4-diazepino may bear a methyl group at the 4 position;~~

(iii)



Serial No. 09/926,712

Response to Office Action of January 14, 2004



in which ~~R<sub>E</sub> is phenyl (which phenyl may bear a fluoro, chloro, C<sub>1-4</sub> alkyl, methoxy or methylsulphonyl substituent), or~~  
 (iii)



~~in which Het is a divalent 5 membered heteroaromatic group containing 1, 2 or 3 heteroatoms selected from O, N and S and having the two ring atoms at which it is connected separated by one ring atom,~~

~~— n is 0 or 1; and~~

~~R<sub>n</sub> is phenyl which may bear one or more R<sub>3</sub> substituents;~~  
 and

R<sub>1c</sub> ~~is and R<sub>1j</sub> are~~ as defined for R<sub>1j</sub> R<sub>1a</sub>,  
 or a physiologically tolerable salt thereof.

2 (canceled):

3 (canceled):

4 (canceled):

5 (canceled):

6 (currently amended): A compound as claimed in Claim 1, in which ~~Y is a CH group and has the conformation that would result from construction from a D-α-aminoacid NH<sub>2</sub>-CH(Cy)-COOH~~ where the NH<sub>2</sub> represents part of X-X.

Serial No. 09/926,712  
Response to Office Action of January 14, 2004

7 (canceled):

8 (previously presented): A compound as claimed in Claim 1, in which Cy represents an optionally  $R_{3a}$  substituted phenyl, naphthyl or cycloalkyl group.

9 (original): A compound as claimed in Claim 8, in which  $R_{3a}$  is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl,  $CONH_2$ ,  $CH_2CONH_2$ , acetylamino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and trifluoromethyl.

10 (previously presented): A compound as claimed in Claim 1, in which Cy is phenyl, 4-aminophenyl, 4-amidophenyl, 4-(N-methyl)amidophenyl, 4-(N,N-dimethyl)amidophenyl, 2-chlorophenyl, 2-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-carboxyphenyl, 3-ethylsulphonylaminophenyl, cyclohexyl or naphth-1-yl.

11 (canceled):

12 (canceled):

13 (canceled):

Serial No. 09/926,712  
Response to Office Action of January 14, 2004

14 (canceled):

15 (canceled):

16 (withdrawn):

17 (withdrawn):


18 (withdrawn):

19 (previously presented): A compound as claimed in Claim 1, in which R<sub>3</sub> is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, t-butyl, pentyl, 2-pentyl or 3-pentyl, isopropylaminomethyl, dimethylaminomethyl, diethylaminomethyl, dimethylaminoethyl, acetyl, hydroxymethyl, hydroxyethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, aminocarbonyl, methylamino, dimethylamino, ethylamino, formylamino, acetylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, isopropylsulphonyl, methylsulphenyl, 1,2,4-triazol-2-yl, 1,2,4-triazol-4-yl, 1,2,3-triazol-4-yl, 1,3-imidazol-1-yl or 1,3-imidazol-4-yl, tetrazol-1-yl, tetrazol-5-yl; methylsulphonamido, ethylsulphonamido, propylsulphonamido, methylaminosulphonyl, ethylaminosulphonyl, propylaminosulphonyl, aminosulphonyl, trifluoromethoxy, trifluoromethyl and trichloromethyl.

20 (currently amended): A compound as claimed in Claim 1, in which Lp is selected from


Serial No. 09/926,712

Response to Office Action of January 14, 2004



where R<sub>8</sub> represents H, OMe, SO<sub>2</sub>Me, F, cyano, amido, amino, NO<sub>2</sub>, Cl or OH.

21 (previously presented): A compound as claimed in Claim 1, in which Lp represents



wherein X<sub>2</sub> is halo, hydrogen, amino, nitro or CONH<sub>2</sub>.

22 (canceled):

23 (previously presented): A compound as claimed in Claim 1, in which R<sub>2</sub> represents:

(i) phenyl optionally being substituted in the 3 and/or 4 position by fluoro, chloro, bromo, iodo, nitro, difluoromethoxy, trifluoromethoxy, amino, trifluoromethyl, methylthio, vinyl, carboxy, acetoxy, MeSO<sub>2</sub>-, hydroxy, methoxy, ethoxy, methyl, methoxycarbonyl, methylamino, ethylamino or

Serial No. 09/926,712  
Response to Office Action of January 14, 2004

amido, and optionally substituted at the 6 position by amino, hydroxy, fluoro, methoxycarbonyl, cyano or aminomethyl; or

(ii) naphth-2-yl optionally substituted at the 6, position by hydroxy and optionally substituted at the 3 position by amino or hydroxy.

24 (canceled):

25 (canceled):

26 (canceled):

27 (original): A pharmaceutical composition, which comprises a compound as claimed in Claim 1 together with at least one pharmaceutically acceptable carrier or excipient.

28 (previously presented): A compound as claimed in Claim 23, in which R<sub>2</sub> represents phenyl substituted in the 4 position by chloro, amino, vinyl, methylamino, methyl or methoxy, optionally at the 3 position with amino or hydroxy, and optionally at the 6 position with amino or hydroxy.

29 (canceled):

30 (canceled):

31 (canceled):

32 (canceled):

33 (canceled):

34 (canceled):

Serial No. 09/926,712  
Response to Office Action of January 14, 2004

35 (canceled):

36 (canceled):

37 (canceled):

38 (canceled):

39 (canceled):

40 (canceled):

41 (canceled):

42 (currently amended): A compound as claimed in Claim 1,  
which is selected from:

1-(3-Amino-4-chlorobenzoyl-D-phenylglyciny1)-4-(4-fluoro-2-methylsulphonylphenyl)piperazine;

~~1-(3-Amino-4-chlorobenzoyl-D-phenylglyciny1)-1'-methyl-4,4'-bispiperidine;~~

1-(3-Amino-4-chlorobenzoyl-D-phenylglyciny1)-4-(2-methylsulphonylphenyl)piperazine;

and physiologically tolerable salts thereof.

43 (previously presented): A pharmaceutical composition,  
which comprises a compound as claimed in Claim 42 together  
with at least one pharmaceutically acceptable carrier or  
excipient.